Form 4: Xeris Biopharma Holdings Executive Reports Stock Transaction
Insider Transaction (Form 4)
Kevin Mcculloch, See Remarks of Xeris Biopharma Holdings, Inc., reported a transaction in 21,918 shares of common stock on August 1, 2026.
Summary
- Tax/exercise-price withholding: disposed of 21,918 Common Stock at $8.08 ($177,097) on August 1, 2026; holds 1,654,208 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Kevin Mcculloch — Officer (See Remarks)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-01 | Tax/exercise-price withholding | Common Stock | 21,918 | $8 | $177.1K | 1,654,208 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-01 | Tax/exercise-price withholding (21,918 shares) |
Keywords
insider transaction, Form 4, XERS, Xeris Biopharma Holdings, Inc., neutral, Kevin Mcculloch
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.